ClearPoint Neuro, Inc.
Financials
Valuation Metrics
ClearPoint Neuro, Inc.'s Market Cap is $321M. At end of 2025 it was $387M. Ranked #2897 of 3,116 in US market (top 93%), #1305 of 1,472 on NASDAQ (top 89%), #183 of 203 in Health Care Equipment & Services (top 90%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $321M | US#2,897/3,116 Sec#183/203 |
| Revenue | $45M | US#2,755/3,116 Sec#195/203 |
| Net Income | $-36M | US—/3,116 Sec—/203 |
| Total Assets | $113M | US#3,057/3,116 Sec#203/203 |
| Net Assets | $27M | US#2,896/3,116 Sec#192/203 |
| Employees | 172 | US#2,502/3,116 Sec#173/203 |
| Value | ||
| P/B | 11.76x | US#2,843/3,116 Sec#184/203 |
| P/S | 7.05x | US#2,567/3,116 Sec#169/203 |
| FCF Yield | -10.36% | US—/3,116 Sec—/203 |
| Profitability | ||
| ROE | -132.52% | US—/3,116 Sec—/203 |
| ROA | -32.05% | US#2,939/3,116 Sec#194/203 |
| Op. Margin | -70.56% | US#2,683/3,116 Sec#190/203 |
| Revenue Growth | 32.51% | US#495/3,116 Sec#28/203 |
| Financial Health | ||
| Debt Ratio | 313.42% | US#2,521/3,116 Sec#186/203 |
| Total Debt | $74M | US#2,551/3,116 Sec#152/203 |
| FCF | $-33M | US#2,471/3,116 Sec#171/203 |
| Cash | $46M | US#2,757/3,116 Sec#181/203 |
| Current Ratio | 6.76x | US#500/3,116 Sec#41/203 |
| Performance | ||
| 1Y Return | -54.86% | US#2,934/3,116 Sec#192/203 |
| 1M Return | -12.45% | US#2,525/3,116 Sec#182/203 |
| From 52W High | -45.68% | US#2,813/3,116 Sec#187/203 |
| 1Y MDD | -54.42% | US#2,794/3,116 Sec#175/203 |
| Trading | ||
| Volume | 778,820 shares | US#1,310/3,116 Sec#79/203 |
| Trading Value | $8M | US#2,118/3,116 Sec#149/203 |
| Per Share | ||
| EPS | $-1.20 | US—/3,116 Sec—/203 |
| BPS | $0.91 | US#2,761/3,116 Sec#189/203 |
Company Info
ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core offerings is the ClearPoint system, designed for the precise placement of deep brain stimulation electrodes, biopsy needles, and for the controlled infusion of medications and laser catheters directly into the brain. It also provides the ClearPoint Neuro Navigation System, which is specifically engineered for MRI suite environments. ClearPoint Neuro maintains strategic partnerships and licensing agreements with prominent institutions and companies, including Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and the University of California, San Francisco. Initially established in 1998 and headquartered in Solana Beach, California, the company operated as MRI Interventions, Inc. before rebranding to ClearPoint Neuro, Inc. in February 2020.